Ultrasound response rate was 65.0% vs 40.0% and relevant biomarkers favored neoadjuvant Eve plus letrozole (Treg/CD4+ T cell, PD-L1; Ki67 index; tumor-infiltrating Tregs). Here, CD4 is linked to neoplasm.